Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853]
Corresponding Author of This Article
Shu-Bin Wang, MD, PhD, Chief Doctor, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, China Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, No. 1120 Lianhua Road, Futian District, Shenzhen 518036, Guangdong Province, China. shubinwang2013@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853]
World J Gastroenterol. Nov 21, 2020; 26(43): 6853-6866 Published online Nov 21, 2020. doi: 10.3748/wjg.v26.i43.6853
Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis
Xue-Ling Kang, Li-Rui He, Yao-Li Chen, Shu-Bin Wang
Xue-Ling Kang, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, Guangdong Province, China
Li-Rui He, Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China
Yao-Li Chen, Department of Pathology, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong Province, China
Shu-Bin Wang, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, China Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, Guangdong Province, China
Author contributions: Kang XL was responsible for the statistical analysis and preparation of manuscript; He LR provided information of the surgical patients; Chen YL provided the patient's pathological and immunohistochemical staining sections; Wang SB is the guarantor of this work and as such, has full access to all the data in the study and takes responsibility for the integrity of the data.
Supported bySanming Project of Shenzhen, No. SZSM201612041; Shenzhen Science and Technology Innovation Commission Project, No. GJHZ20180420180754917 and No. ZDSYS20190902092855097; and Postdoctoral Science Foundation of China, No. 2018M633095.
Institutional review board statement: The study was reviewed and approved by the Peking University Shenzhen Hospital Institutional Review Board.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: Dataset available from the corresponding author at shubinwang2013@163.com. Participants gave informed consent for data sharing.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Corresponding author: Shu-Bin Wang, MD, PhD, Chief Doctor, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, China Cancer Institute of Shenzhen-Peking University-Hong Kong University of Science and Technology Medical Center, No. 1120 Lianhua Road, Futian District, Shenzhen 518036, Guangdong Province, China. shubinwang2013@163.com
Received: June 19, 2020 Peer-review started: June 19, 2020 First decision: September 12, 2020 Revised: September 29, 2020 Accepted: October 19, 2020 Article in press: October 19, 2020 Published online: November 21, 2020 Processing time: 153 Days and 14.2 Hours
ARTICLE HIGHLIGHTS
Research background
The role of doublecortin-like kinase 1 (DCLK1) and leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5) in patients with stage II/III colorectal cancer (CRC) remains uncertain.
Research motivation
Designing novel targeting drugs based on specific cancer stem cell (CSC) markers is the goal of CSC therapy. Due to the lack of clear understanding of the potency of DCLK1 in CRC in previous studies, its expression and clinical significance were determined in an extensive collection of CRC samples.
Research objectives
We determined the clinical significance of DCLK1 and Lgr5 as CSC markers for the recurrence and survival of stage II/III CRC patients.
Research methods
The expression of DCLK1 and Lgr5 in CRC tissue sections from 92 patients was detected by immunohistochemistry.
Research results
In this study, we have found a positive correlation between the expression of DCLK1 and Lgr5, suggesting that DCLK1 and Lgr5 are involved in the malignant pathological development of CRC. High DCLK1 expression could predict the risk of recurrence and survival in CRC patients after surgery.
Research conclusions
DCLK1 may be a potential CSC marker for the recurrence and survival of CRC patients.
Research perspectives
Our research raises the possibility that treatments targeting DCLK1 could be beneficial in CRC patients.
